| Pepine, Carl |
| Active, not recruiting | 4 | 2476 | US | High dose potent statin, atorvastatin or rosuvastatin, ACE-I (lisinopril) or ARB (losartan), ACE-I or ARB, Aspirin, Lifestyle Counseling, PACE Lifestyle Intervention, Quality of Life Questionnaires, QOL | University of Florida, United States Department of Defense | Coronary Artery Disease | 02/25 | 09/25 | | |
NCT02133872: Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients |
|
|
| Recruiting | 4 | 35 | US | Minocycline dose escalation | University of Florida, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension | 01/24 | 01/24 | | |
NCT06246396: Antihypertensive Mechanisms of Minocycline in Resistant Hypertension |
|
|
| Recruiting | 4 | 120 | US | Minocycline Hydrochloride, Minocycline, Minocin, Placebo | University of Florida, Emory University, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension, Resistant to Conventional Therapy | 07/28 | 07/28 | | |
NCT02438306: CardiAMP™ Cell Therapy for Heart Failure Trial |
|
|
| Active, not recruiting | 3 | 125 | Canada, US | Autologous cell therapy, Sham | BioCardia, Inc. | Heart Failure, Systolic | 12/24 | 12/26 | | |
NCT02213575: Study 3: Minocycline Decreases Microglia Activation |
|
|
| Not yet recruiting | 2 | 9 | US | Minocycline | University of Florida, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension | 04/25 | 10/25 | | |
NCT02133885: Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients |
|
|
| Withdrawn | 1/2 | 56 | US | Minocycline Group, Placebo Group | University of Florida, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension | 03/24 | 03/24 | | |
NCT05925608: Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells |
|
|
| Enrolling by invitation | 1/2 | 39 | US | CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs), Diagnostic Catheterization | BioCardia, Inc. | Heart Failure, Systolic | 07/25 | 07/25 | | |
NCT04723303: Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) |
|
|
| Completed | 1 | 10 | US | Umbilical Cord Lining Stem Cells | University of Florida, Restem, LLC. | Polymyositis, Dermatomyositis | 12/23 | 03/24 | | |
NCT00832702: Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction |
|
|
| Active, not recruiting | N/A | 433 | US | Cardiac MRI | Cedars-Sinai Medical Center, National Heart, Lung, and Blood Institute (NHLBI), University of Florida, University of Pittsburgh | Cardiovascular Disease | 09/15 | 08/51 | | |
| Completed | N/A | 41 | US | Gene Expression | University of Florida, National Heart, Lung, and Blood Institute (NHLBI) | Gut Inflammation | 04/22 | 04/24 | | |
| Active, not recruiting | N/A | 292 | US | Stool Sample and Blood Sample | University of Florida, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension | 10/24 | 10/24 | | |
| Recruiting | N/A | 135 | US | CardioFlux | Genetesis Inc. | Ischemic Heart Disease, Coronary Microvascular Disease, Angina, Myocardial Ischemia | 12/24 | 12/24 | | |
NCT02728154: The Role of Gut Microbiota in Heart Failure and Pre-Heart Failure With Preserved Ejection Fraction |
|
|
| Recruiting | N/A | 220 | US | Blood Sample, Stool Sample | University of Florida, National Heart, Lung, and Blood Institute (NHLBI) | Heart Failure | 06/25 | 06/25 | | |
| Smith, Steven R |
NCT06246396: Antihypertensive Mechanisms of Minocycline in Resistant Hypertension |
|
|
| Recruiting | 4 | 120 | US | Minocycline Hydrochloride, Minocycline, Minocin, Placebo | University of Florida, Emory University, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension, Resistant to Conventional Therapy | 07/28 | 07/28 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
ISIS, NCT02463240: Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 463588 |
|
|
| Active, not recruiting | 2 | 15 | US | ISIS 463588, Placebo, 0.9% Sterile saline | Translational Research Institute for Metabolism and Diabetes, Florida, Isis Pharmaceuticals | Obesity | 10/16 | | | |
NCT00977457: Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery |
|
|
| Active, not recruiting | 1 | 1045 | US | DNA analysis, DNA methylation analysis, RNA analysis, gene expression analysis, polymerase chain reaction, diagnostic laboratory biomarker analysis, therapeutic conventional surgery, Undergo robotic prostatectomy or cystoprostatectomy | City of Hope Medical Center, National Cancer Institute (NCI) | Prostate Cancer | 07/16 | 12/24 | | |
NCT02817659: To Determine Tolerability to Glucagon Infusion in Obese Subjects |
|
|
| Active, not recruiting | 1 | 20 | US | Glucagon | AdventHealth Translational Research Institute | Obesity | 01/17 | 12/24 | | |
NCT03139305: Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects |
|
|
| Active, not recruiting | 1 | 30 | US | Glucagon, Placebo | AdventHealth Translational Research Institute | Obesity | 02/18 | 12/24 | | |
MCC-21113, NCT05316129: Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer |
|
|
| Recruiting | 1 | 48 | US | Follicle Stimulating Hormone Receptor T Cells | H. Lee Moffitt Cancer Center and Research Institute, Anixa Biosciences, Inc. | Ovarian Cancer | 03/25 | 03/29 | | |
NCT06313528: A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 |
|
|
| Recruiting | 1 | 74 | US | LY3437943, Placebo | Eli Lilly and Company | Obesity | 10/25 | 10/25 | | |
| Active, not recruiting | N/A | 56 | US | Exercise | AdventHealth Translational Research Institute, Sanford-Burnham Medical Research Institute, Takeda | Obesity, Disorder of Lipid Storage and Metabolism, Lipid Metabolism Disorders, Metabolic Disorder | 12/14 | 12/24 | | |
| Active, not recruiting | N/A | 36 | US | | AdventHealth Translational Research Institute, Sanford-Burnham Medical Research Institute, Pennington Biomedical Research Center, Boston University, Tufts University | Polycystic Ovary Syndrome, Metabolic Diseases, Overweight | 02/15 | 12/24 | | |
NCT01441687: Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome |
|
|
| Active, not recruiting | N/A | 243 | US | laboratory biomarker analysis, transrectal prostate biopsy | City of Hope Medical Center, National Cancer Institute (NCI) | Conditions Influencing Health Status, Healthy, Prostate Cancer | 06/16 | 12/24 | | |
| Active, not recruiting | N/A | 27 | US | Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS), Adipose tissue biopsies, FSIGTT/ RMR | AdventHealth Translational Research Institute, Sanford-Burnham Medical Research Institute | Obesity | 12/24 | 12/24 | | |
| Active, not recruiting | N/A | 108 | US | DEXA, Magnetic Resonance (MR) Assessment of the Abdomen, MR assessment of Whole Body Fat, Adipose tissue biopsy, Oral glucose tolerance test | AdventHealth Translational Research Institute | PCOS | 12/25 | 12/25 | | |
DAC, NCT05379348: Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease |
|
|
| Active, not recruiting | N/A | 1423 | US | Cognitive Assessment, MoCA | AdventHealth Translational Research Institute, Davos Alzheimer's Collaborative | Alzheimer Disease | 12/24 | 12/24 | | |
NCT01827527: Magnetic Resonance & Optical Spectroscopy Validation |
|
|
| Recruiting | N/A | 150 | US | | AdventHealth Translational Research Institute | Validation Studies, Magnetic Resonance Spectroscopy | 12/24 | 12/24 | | |
| Raizada, Mohan |
NCT02133872: Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients |
|
|
| Recruiting | 4 | 35 | US | Minocycline dose escalation | University of Florida, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension | 01/24 | 01/24 | | |
NCT02133885: Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients |
|
|
| Withdrawn | 1/2 | 56 | US | Minocycline Group, Placebo Group | University of Florida, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension | 03/24 | 03/24 | | |
| Leach, Dana |
NCT02133872: Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients |
|
|
| Recruiting | 4 | 35 | US | Minocycline dose escalation | University of Florida, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension | 01/24 | 01/24 | | |
NCT06246396: Antihypertensive Mechanisms of Minocycline in Resistant Hypertension |
|
|
| Recruiting | 4 | 120 | US | Minocycline Hydrochloride, Minocycline, Minocin, Placebo | University of Florida, Emory University, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension, Resistant to Conventional Therapy | 07/28 | 07/28 | | |
NCT02133885: Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients |
|
|
| Withdrawn | 1/2 | 56 | US | Minocycline Group, Placebo Group | University of Florida, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension | 03/24 | 03/24 | | |
